이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AxoGen 관리

관리 기준 확인 1/4

AxoGen's CEO는 Karen Zaderej, Sep2011 에 임명되었습니다 의 임기는 12.75 년입니다. 총 연간 보상은 $ 5.53M, 12.6% 로 구성됩니다. 12.6% 급여 및 87.4% 보너스(회사 주식 및 옵션 포함). 는 $ 8.18M 가치에 해당하는 회사 주식의 2.62% 직접 소유합니다. 8.18M. 경영진과 이사회의 평균 재임 기간은 각각 0.9 년과 3.8 년입니다.

주요 정보

Karen Zaderej

최고 경영자

US$5.5m

총 보상

CEO 급여 비율	12.6%
CEO 임기	12.8yrs
CEO 소유권	2.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Jun 12

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26

CEO 보상 분석

Karen Zaderej 의 보수는 AxoGen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$6m	US$700k	-US$22m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	US$4m	US$674k	-US$29m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$32m
Dec 31 2021	US$5m	US$651k	-US$27m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$4m	US$561k	-US$24m
Sep 30 2020	n/a	n/a	-US$25m
Jun 30 2020	n/a	n/a	-US$29m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$1m	US$605k	-US$29m
Sep 30 2019	n/a	n/a	-US$27m
Jun 30 2019	n/a	n/a	-US$26m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$4m	US$575k	-US$22m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	US$4m	US$463k	-US$10m

보상 대 시장: Karen 의 총 보상 ($USD 5.53M )은 US 시장( $USD 2.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Karen 의 보상이 증가했습니다.

CEO

Karen Zaderej (62 yo)

12.8yrs

테뉴어

US$5,534,681

보상

Ms. Karen Zaderej has been President and Chief Executive Officer of AxoGen, Inc. since September 30, 2011. She is Independent Director of EyePoint Pharmaceuticals, Inc. from July 2022. She was the Director...

리더십 팀

이름	위치	테뉴어	보상	소유권
Karen Zaderej	Chairman	12.8yrs	US$5.53m	2.62% $ 8.8m
Nir Naor	Chief Financial Officer	less than a year	US$509.68k	데이터 없음
Erick DeVinney	Chief Innovation Officer	less than a year	US$1.51m	0.29% $ 982.8k
Todd Puckett	Vice President of Operations	less than a year	데이터 없음	데이터 없음
Harold Tamayo	Vice President of Finance & Investor Relations	no data	데이터 없음	데이터 없음
Marc Began	Executive VP	1.3yrs	데이터 없음	데이터 없음
Doris Quackenbush	Vice President of Sales	2.5yrs	데이터 없음	데이터 없음
Jens Kemp	Chief Marketing Officer	1.4yrs	데이터 없음	데이터 없음
Ivica Ducic	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: AXGN 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Karen Zaderej	Chairman	12.8yrs	US$5.53m	2.62% $ 8.8m
Paul Thomas	Independent Director	3.8yrs	US$220.00k	0.022% $ 73.2k
Guido Neels	Independent Director	8.9yrs	US$217.50k	0.16% $ 526.3k
Bruce Mast	Member of Board of Advisor	no data	데이터 없음	데이터 없음
David Muir	Member of Board of Advisor	no data	데이터 없음	데이터 없음
John Johnson	Independent Director	3yrs	US$215.00k	0.015% $ 49.8k
Kathy Weiler	Independent Director	less than a year	US$293.37k	데이터 없음
Alan Levine	Independent Director	5.2yrs	US$217.50k	0.042% $ 140.8k
Amy Wendell	Independent Lead Director	7.8yrs	US$255.00k	0.18% $ 619.4k
William Burke	Independent Director	2yrs	US$220.00k	0.037% $ 123.4k
Joseph Tyndall	Independent Director	1.6yrs	US$205.00k	0% $ 0

3.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: AXGN 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

AxoGen 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

Chairman exercised options and sold US$302k worth of stock

Vice President of Operations recently sold US$320k worth of stock

AxoGen, Inc. Announces Executive Changes

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Recent updates

Forecast breakeven date pushed back to 2026

Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Forecast breakeven date moved forward to 2025

Axogen, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

New minor risk - Shareholder dilution

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Chairman exercised options and sold US$302k worth of stock

Consensus EPS estimates fall by 39%

Vice President of Operations recently sold US$320k worth of stock

AxoGen, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022)

Forecast breakeven date pushed back to 2026

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Insider recently sold US$94k worth of stock

AxoGen, Inc. Announces CFO Changes

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023

AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Price target decreased by 13% to US$14.20

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector

Independent Director recently bought US$66k worth of stock

Independent Director recently bought US$61k worth of stock

Axogen, Inc. Provides Revenue Guidance for the Year 2023

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Director recently sold US$366k worth of stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director recently sold US$69k worth of stock

AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Executive VP & CFO exercised options and sold US$58k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.5% to US$16.25

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

Executive VP & CFO exercised options and sold US$318k worth of stock

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

AxoGen, Inc. to Report Q4, 2022 Results on Mar 14, 2023

Forecast to breakeven in 2025

Chairman exercised options to buy US$282k worth of stock.

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Price target decreased to US$17.75

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

AxoGen, Inc. Updates Earnings Guidance for the Full Year 2022

Axogen, Inc. Announces Directorate Changes

AxoGen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Is AxoGen (NASDAQ:AXGN) A Risky Investment?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

Eric Sandberg, Current Chief Commercial Officer Will Be Leaving AxoGen, Inc

Axogen estimates Q2 revenue above consensus, reaffirms guidance

Axogen, Inc. Appoints William Burke to Board of Directors